Most IV clinic owners underestimate how much preparation drives valuation. This checklist walks you through every step — from medical director succession to membership documentation — so you can exit on your terms at a 3x–5.5x multiple.
Selling an IV therapy clinic in the lower middle market ($1M–$5M revenue) is fundamentally different from selling a traditional retail or service business. Buyers — whether med spa rollup platforms, physician groups, or SBA-financed first-time buyers — will scrutinize your medical director structure, state licensing compliance, compounding pharmacy relationships, and the credibility of your recurring membership revenue before making an offer. The industry's rapid growth has attracted sophisticated acquirers who know exactly what to look for and where to apply valuation discounts. The average exit timeline for a well-prepared IV clinic owner is 12–18 months from decision to close. Owners who begin preparation early consistently command higher multiples, face fewer re-trades during due diligence, and close faster. This checklist is organized into three phases — Foundation (Months 1–6), Marketability (Months 7–12), and Go-to-Market (Months 12–18) — with quick wins you can act on immediately regardless of where you are in the process.
Get Your Free IV Therapy Clinic Exit ScoreRecruit and onboard a replacement medical director
If you currently serve as your clinic's medical director, this is the single most important step you can take. Buyers will apply a steep discount — or walk away entirely — if the medical director role is not transferable. Identify a physician willing to sign a formal medical supervision agreement, introduce them to staff and protocols, and begin transitioning oversight responsibilities. The replacement physician should be in place and documented at least 12 months before your target close date so buyers see a proven track record without you.
Formalize clinical protocols into written SOPs reviewed by a healthcare compliance attorney
Every infusion service your clinic offers — from basic hydration drips to NAD+ therapy, glutathione pushes, and peptide injections — must be backed by a written clinical protocol signed off by your medical director and reviewed by a healthcare attorney familiar with your state's scope of practice rules. Buyers financing with SBA loans will require this documentation. Missing or informal protocols are a red flag that triggers due diligence delays and price reductions.
Audit all state licensing, health department permits, and nurse credentials
Pull certificates for every operating location, confirm your health department permits are current, and audit the license status and expiration dates for every RN, LPN, or NP on staff. State regulations governing nurse-only IV administration and medical supervision vary significantly and are evolving. Identify any gaps now — a lapsed license or expired permit discovered during buyer due diligence can kill or re-trade a deal at the worst possible moment.
Engage a CPA to produce 3 years of accrual-based financial statements
Cash-basis bookkeeping is common among owner-operated IV clinics but is not acceptable for a credible sale process. Have a CPA recast your financials on an accrual basis for the trailing 3 years, normalize owner compensation, and prepare a documented add-back schedule. Buyers and SBA lenders will use these statements to underwrite the deal. Clean financials directly determine the EBITDA figure that drives your valuation multiple.
Audit compounding pharmacy relationships and ensure contracts include assignability clauses
If your clinic relies on a 503A or 503B compounding pharmacy for NAD+, glutathione, high-dose vitamin C, or other infusion products, confirm that your supplier agreements are in writing and include a clause allowing the contract to be assigned to a new owner. Buyers are acutely aware of FDA and state pharmacy board scrutiny in this area. An undocumented or non-assignable compounding relationship is both a regulatory risk and an operational continuity risk that acquirers will price into their offer.
Build or expand your membership program and document month-over-month retention
Recurring membership revenue is the most powerful valuation driver in the IV therapy clinic market. Buyers underwriting at 3x–5.5x EBITDA are paying for predictable cash flow — walk-in revenue alone does not support premium multiples. If you have fewer than 100 active members, prioritize growing this base. If you have 200+, begin tracking and exporting monthly retention rates, churn percentages, and average revenue per member so the data tells a compelling recurring revenue story in your CIM.
Create an exportable customer database with visit frequency, lifetime value, and membership history
Buyers will ask for this in due diligence and the inability to produce it is a significant credibility problem. Build a clean, exportable dataset from your booking or POS system that includes each client's visit history, total spend, membership status, and tenure. Redact names for initial presentations per HIPAA guidelines but ensure the underlying data is ready for release under NDA. This dataset is what transforms anecdotal claims about loyal clientele into verifiable buyer confidence.
Diversify your service menu to increase average revenue per visit
Clinics offering only basic hydration drips are perceived as commoditized and vulnerable to price competition. Adding NAD+ therapy, peptide injections, weight loss programs (e.g., semaglutide support), or Myers' Cocktail upgrades creates upsell pathways that increase revenue per visit and per member. Document your revenue mix by service line so buyers can see the contribution of higher-margin offerings and the upside potential of further expansion.
Formalize referral partnerships with gyms, concierge medicine practices, and corporate wellness programs
Document every referral relationship in a written agreement or at minimum in a letter of relationship with revenue attribution data. Referral partnerships with gyms, executive health clinics, and concierge physicians demonstrate market integration and community credibility that new competitors cannot replicate overnight. These relationships are a defensible competitive moat that buyers — particularly rollup platforms — actively value.
Actively manage your online reputation and document Google review trajectory
A 4.8+ star Google rating with a high review count is not just a marketing asset — it is a due diligence data point that signals client satisfaction, staff competency, and brand trust. If your rating is below 4.5 or your review count is thin, invest in a systematic review request process for satisfied clients. Export your review history and rating trend as part of your marketing materials. Buyers paying 4x–5x EBITDA want evidence that the brand travels beyond your personal relationships.
Engage a healthcare-specialized M&A advisor or business broker
IV therapy clinics sit at the intersection of healthcare regulation, cash-pay medical models, and wellness industry dynamics — a generalist business broker will underprice your business and attract unqualified buyers. Work with an advisor who has closed cash-pay medical transactions, understands SBA lending requirements for healthcare-adjacent businesses, and can run a structured process targeting med spa rollup platforms, physician buyers, and qualified individual acquirers simultaneously.
Prepare a Confidential Information Memorandum (CIM) highlighting recurring revenue, compliance posture, and growth runway
Your CIM is the document that gets buyers to the letter of intent stage. It must tell a coherent story: transferable medical director, documented membership revenue, clean financials, compliant clinical protocols, and a clear reason why the business will perform as well — or better — under new ownership. Work with your advisor to build a CIM that pre-answers the questions every sophisticated IV clinic buyer will ask and presents your add-back EBITDA in a format SBA lenders will accept.
Resolve any open malpractice claims, state board complaints, or unresolved regulatory matters
Any unresolved legal, licensing, or regulatory matter will surface in due diligence and become a negotiating lever for buyers to reduce price, increase escrow holdbacks, or demand indemnification provisions that create ongoing financial exposure for you post-close. Engage healthcare counsel now to resolve or document the resolution of any open matters. A clean compliance record is a prerequisite for achieving top-of-range multiples.
Structure your deal expectations around realistic terms including earnouts and seller notes
Most IV therapy clinic transactions are structured as full asset purchases with 10–20% seller earnouts tied to 12-month post-close revenue retention, or SBA 7(a) loans with a seller note covering the remainder. Buyers using SBA financing may require you to carry 5–10% of the purchase price as a seller note on standby. Understanding these structures in advance prevents surprises at the LOI stage and helps you evaluate competing offers on an apples-to-apples basis.
Plan your post-close transition and communicate it to key staff and the medical director
Buyers will ask how long you are willing to stay post-close for transition and training. A 30–90 day transition with a willing medical director and stable key staff dramatically increases buyer confidence and reduces the risk premium built into their offer. Have honest conversations with your medical director and any lead nurses about transition expectations before you go to market — surprises here during due diligence are a common cause of deal re-trades.
See What Your IV Therapy Clinic Business Is Worth
Free exit score, valuation range, and personalized action plan — 5 minutes.
Most IV therapy clinics in the $1M–$5M revenue range trade at 3x–5.5x adjusted EBITDA. The specific multiple depends on the transferability of your medical director agreement, the strength and size of your membership program, revenue concentration risk, compliance posture, and whether you have multiple locations. A clinic with a transferable physician agreement, 200+ active members, and clean financials will consistently command the high end of that range, while a single-location clinic with an owner-serving-as-medical-director and walk-in-only revenue will land at or below 3x.
Well-prepared sellers typically take 12–18 months from the decision to exit through closing. This includes 6–12 months of pre-market preparation — financial clean-up, medical director succession, SOP documentation — followed by 3–6 months of active marketing, due diligence, and SBA loan underwriting. Sellers who go to market without preparation frequently experience re-trades, extended timelines, and lower final prices than prepared peers.
Yes. IV therapy clinics are SBA-eligible businesses, and most lower middle market transactions in this space involve SBA 7(a) financing covering 75–90% of the purchase price. However, SBA lenders will require 3 years of tax returns and CPA-prepared financials, a documented medical director agreement, clean licensing, and evidence of a viable business that is not entirely dependent on the current owner. Sellers whose businesses cannot pass SBA lender scrutiny will be limited to all-cash buyers, which significantly narrows the buyer pool and reduces competitive tension.
Yes, but you must solve this before going to market. The medical director role is a regulatory and operational dependency that buyers treat as existential risk. If you are the sole medical director with no succession plan, most acquirers will heavily discount your offer or require a lengthy transition period with significant earnout exposure. The solution is to recruit a replacement physician, onboard them under a formal supervision agreement, and allow the arrangement to season for at least 12 months before you begin marketing the business.
Yes — this is one of the top due diligence concerns for every category of buyer. Corporate practice of medicine laws vary by state and can prohibit non-physicians from owning a medical practice, require specific ownership structures, or mandate physician oversight arrangements. Buyers financing with SBA loans will have their lender's counsel review these issues specifically. The best way to address this concern is to engage a healthcare compliance attorney before you go to market, confirm your clinic structure is compliant, and document that opinion in writing for buyers.
Buyers are skeptical of membership claims that are not backed by data. To make your recurring revenue credible, you need at minimum 12 months of month-over-month membership count, monthly recurring revenue, retention rate, and churn data in a clean exportable format. If your membership program is informal or tracked manually, invest in a proper booking and membership management system now. Buyers financing at 4x–5x EBITDA are underwriting your future cash flows — documented recurring revenue is the foundation of that underwriting.
This requires careful judgment. Telling staff too early can trigger anxiety, turnover, and operational disruption — particularly among licensed nurses who are easy to recruit. However, your medical director and any key clinical lead will likely need to be brought into the conversation during due diligence. Most advisors recommend keeping the circle tight until an LOI is signed, then communicating thoughtfully to key staff with a clear retention and transition plan. Buyers will want assurances about staff continuity, so demonstrating a plan to retain critical personnel is part of your preparation.
The single biggest mistake is going to market before the business can stand on its own without the owner. When the owner is the medical director, the primary client relationship manager, and the face of the brand, buyers see an enormous transition risk they cannot quantify — so they price it in with a low multiple or heavy earnout. The clinics that achieve the strongest exits have replaced the owner's operational role, documented their recurring revenue credibly, and built a team that buyers are confident will perform after the handoff.
More IV Therapy Clinic Seller Guides
More Exit Checklists
Get your IV Therapy Clinic exit score, estimated valuation, and a step-by-step action plan — free, in 5 minutes.
Start Your Free Exit AssessmentFree forever · No broker needed · Takes 5 minutes
For Buyers
For Sellers